Evidence map›Paper›PMID 40128220›Full record

ArticleNature communications2025

A combined adjuvant and ferritin nanocage based mucosal vaccine against Streptococcus pneumoniae induces protective immune responses in a murine model.

Tien Duc Nguyen, Hoang Duy Le, Giang Chau Dang, Hyun Seok Jung, Yoonjoo Choi, Koemchhoy Khim, Young Kim, Shee Eun Lee, Joon Haeng Rhee

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. A Modular Vaccine Platform Against SARS-CoV-2 Based on Self-Assembled Protein Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Tien Duc NguyenClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea.
Hoang Duy LeClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea.ORCID http://orcid.org/0009-0000-9350-2840
Giang Chau DangClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea.ORCID http://orcid.org/0009-0007-7313-7728
Hyun Seok JungCombinatorial Tumor Immunotherapy MRC, Chonnam National University Medical School, Hwasun-gun, Jeonnam, Republic of Korea.
Yoonjoo ChoiCombinatorial Tumor Immunotherapy MRC, Chonnam National University Medical School, Hwasun-gun, Jeonnam, Republic of Korea.ORCID http://orcid.org/0000-0001-9687-8093
Koemchhoy KhimClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea.
Young KimDepartment of Oral Pathology, Chonnam National University School of Dentistry, Gwangju, Republic of Korea.
Shee Eun LeeClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea. selee@chonnam.ac.kr.ORCID http://orcid.org/0000-0002-2023-3317
Joon Haeng RheeClinical Vaccine R&D Center, Chonnam National University, Hwasun-gun, Jeonnam, Republic of Korea. jhrhee@chonnam.ac.kr.ORCID http://orcid.org/0000-0003-4018-3203

Funding

Korea Health Industry Development Institute (KHIDI) RS-2022-KH127978(HV22C0079)National Research Foundation of Korea (NRF) NRF-2019R1A5A2027521National Research Foundation of Korea (NRF) NRF-2020M3A9G3080282National Research Foundation of Korea (NRF) NRF-2020R1A5A2031185
6 · The paper itself

Abstract

Protein nanocages are multimeric structures that can be engineered to mimic the molecular conformation of microorganisms. Based on previous findings showing that a mucosal FlaB-tPspA fusion (flagellin fused with truncated PspA antigen of Streptococcus pneumoniae) vaccine-induced protective immune response against S. pneumoniae, we develop a ferritin nanocage vaccine displaying multivalent presentation of both antigen and adjuvant on a nanocarrier using the SpyTag/SpyCatcher strategy. The 1:1 antigen/adjuvant nanocage is further used as a mucosal vaccine, which can translocate to draining lymph nodes with higher efficiency than fusion vaccine. Moreover, intranasal immunization with the nanocage vaccine significantly enhances mucosal immune responses with more efficient B-cell memory generation and antibody maturation, as well as more balanced (Th1/Th2) immune responses with increased IFN-γ and IL-17 production, comparing with fusion vaccine. Mice immunized with the nanocage vaccine exhibited enhanced protection against lethal infection compare to the FlaB-tPspA fusion group. Our study thus demonstrates the effectiveness of an all-in-one nanocage mucosal vaccine platform, which guarantees enhanced protection with balanced immune responses.

Indexed as

Adjuvants, ImmunologicFerritinsImmunity, MucosalPneumococcal InfectionsPneumococcal VaccinesStreptococcus pneumoniaeAdministration, IntranasalAnimalsAntibodies, BacterialBacterial ProteinsDisease Models, AnimalFemaleMiceMice, Inbred BALB CAdjuvants, ImmunologicAntibodies, BacterialBacterial ProteinsFerritinsPneumococcal Vaccines

Identifiers

PMID40128220
PMCPMC11933286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.